Table 2.
Patient characteristics in the training and the validation cohorts.
| Characteristics a | Training set | Validating set | P |
|---|---|---|---|
| n = 265 | n = 159 | ||
| Live birth, n (%) | 79 (29.81) | 35 (22.01) | 0.080 |
| Age, years | 34.05 ± 4.79 | 34.26 ± 4.52 | 0.652 |
| Infertility duration, Years | 4.27 ± 3.41 | 4.57 ± 3.91 | 0.196 |
| BMI, kg/m2 | 21.41 ± 2.82 | 21.14 ± 2.74 | 0.331 |
| AMH, IU/L | 3.07 ± 2.83 | 3.76 ± 3.37 | 0.195 |
| FSH, IU/L | 8.65 ± 3.77 | 7.98 ± 2.13 | 0.087 |
| LH, IU/L | 5.27 ± 2.68 | 5.34 ± 2.87 | 0.822 |
| E2, pg/ml | 53.33 ± 15.78 | 46.60 ± 12.07 | 0.285 |
| T, ng/ml | 0.43 ± 0.24 | 0.46 ± 0.26 | 0.723 |
| Type of adenomyosis, n (%) | 0.721 | ||
| Diffuse | 173 (65.29) | 103 (64.78) | |
| Focal | 92 (34.71) | 59 (35.22) | |
| Uterine diameters prior to ET | |||
| Width diameter, cm | 5.41 ± 1.14 | 5.38 ± 1.13 | 0.415 |
| Anteroposterior diameter, cm | 5.21 ± 1.11 | 5.30 ± 1.11 | 0.808 |
| Long diameter, cm | 5.56 ± 1.05 | 5.67 ± 1.09 | 0.300 |
| Uterine volume, cm3 | 84.81 ± 40.66 | 87.66 ± 40.35 | 0.485 |
| Stage of embryo transfer | 0.107 | ||
| Cleavage, n (%) | 53 (20.00) | 25 (13.84) | |
| Blastocyst, n (%) | 212 (80.00) | 89 (86.16) | |
| Protocol of FET | 0.219 | ||
| HRT | 115 (43.40) | 58 (36.48) | |
| GnRHa-HRT | 104 (39.25) | 76 (47.80) | |
| NC | 46 (17.35) | 25 (15.72) | |
| Endometrial thickness (mm) | 9.87 ± 2.72 | 9.91 ± 2.62 | 0.889 |
| Pregnancy type | 0.193 | ||
| No pregnancy | 142 (53.58) | 99 (62.26) | |
| Singleton pregnancy, n (%) | 71 (26.79) | 37 (23.27) | |
| Twin pregnancy, n (%) | 52 (19.62) | 23 (14.47) |
BMI, body mass index; AMH, anti-Mullerian hormone; FSH, follicle-stimulating hormone; E2, estrogen; T, testosterone; ET, embryo transfer; HRT, hormone replacement therapy; NC, nature cycle.
a
Continuous variables are expressed as mean ± SD and categorical variables as absolute frequencies, n (%).
*P < 0.05 was considered statistically significant.